[go: up one dir, main page]

GB202108544D0 - Compounds and their use for the treatment of alpha1-antitrypsin deficiency - Google Patents

Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Info

Publication number
GB202108544D0
GB202108544D0 GBGB2108544.4A GB202108544A GB202108544D0 GB 202108544 D0 GB202108544 D0 GB 202108544D0 GB 202108544 A GB202108544 A GB 202108544A GB 202108544 D0 GB202108544 D0 GB 202108544D0
Authority
GB
United Kingdom
Prior art keywords
alpha1
compounds
treatment
antitrypsin deficiency
antitrypsin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2108544.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Z Factor Ltd
Original Assignee
Z Factor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Z Factor Ltd filed Critical Z Factor Ltd
Priority to GBGB2108544.4A priority Critical patent/GB202108544D0/en
Publication of GB202108544D0 publication Critical patent/GB202108544D0/en
Priority to PCT/GB2022/051506 priority patent/WO2022263820A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2108544.4A 2021-06-15 2021-06-15 Compounds and their use for the treatment of alpha1-antitrypsin deficiency Ceased GB202108544D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2108544.4A GB202108544D0 (en) 2021-06-15 2021-06-15 Compounds and their use for the treatment of alpha1-antitrypsin deficiency
PCT/GB2022/051506 WO2022263820A1 (en) 2021-06-15 2022-06-15 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2108544.4A GB202108544D0 (en) 2021-06-15 2021-06-15 Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Publications (1)

Publication Number Publication Date
GB202108544D0 true GB202108544D0 (en) 2021-07-28

Family

ID=76954611

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2108544.4A Ceased GB202108544D0 (en) 2021-06-15 2021-06-15 Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Country Status (2)

Country Link
GB (1) GB202108544D0 (en)
WO (1) WO2022263820A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795890A (en) * 1995-09-27 1998-08-18 Ono Pharmaceutical Co., Ltd. Sulfonamide derivatives
TW499412B (en) * 1996-11-26 2002-08-21 Dimensional Pharm Inc Aminoguanidines and alkoxyguanidines as protease inhibitors
US20030134846A1 (en) 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
EP1628970A2 (en) * 2003-04-30 2006-03-01 The Institutes of Pharmaceutical Discovery, LLC Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
JP2007538106A (en) * 2004-05-20 2007-12-27 イーラン ファーマスーティカルズ、インコーポレイテッド N-cyclic sulfonamide inhibitors of γ-secretase
GT200600429A (en) * 2005-09-30 2007-04-30 ORGANIC COMPOUNDS
WO2012128582A2 (en) * 2011-03-23 2012-09-27 Hyundai Pharm Co., Ltd. A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
US11365192B2 (en) * 2017-08-10 2022-06-21 Taisho Pharmaceutical Co., Ltd. Pyridine compound substituted with azole
GB201820450D0 (en) * 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency
TW202116303A (en) * 2019-10-02 2021-05-01 美商維泰克斯製藥公司 Methods of treatment for alpha-1 antitrypsin deficiency

Also Published As

Publication number Publication date
WO2022263820A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
ZA202103977B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
IL288061A (en) Compounds and methods for the treatment of covid-19
GB202416189D0 (en) Methods for the prophylaxis and treatment of Covid and Covid-19
GB201918414D0 (en) Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201918413D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
ZA202207493B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108572D0 (en) Therapeutic compounds and their use
GB202019475D0 (en) Therapeutic compounds and their use
IL309172A (en) Valbenazine for use in the add-on treatment of schizophrenia
GB201918404D0 (en) Compounds and their use for the treatment of aplha1-antitrypsin deficiency
ZA202307970B (en) Compounds for use in the treatment and prevention of covid- 19
GB201918416D0 (en) Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB202108544D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108542D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108543D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
IL312428A (en) Use of maribavir for the treatment of and treatment regimens thereof
GB202108523D0 (en) Compositions and their use for the treatment of alpha1-antitrypsin deficiency
HK40076794A (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
IL282718A (en) Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
HK40111012A (en) Compositions and their use for the treatment of alpha1-antitrypsin deficiency
GB201820452D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB201820451D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB201820455D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB2610895B (en) Composition for use in the treatment and/or prevention of mycotoxic disease
GB202019762D0 (en) Compounds for use in treatment and prophylaxis

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)